Depression and Anxiety Screening

Depression and anxiety screening is the use of brief, validated questionnaires to identify people with probable depressive or anxiety disorders who might otherwise go undetected in general medical care. Because these conditions are common, often unrecognised, and treatable, screening aims to bring detection earlier and to connect identified individuals with assessment and care.

Definition

Depression and anxiety screening is the systematic application of brief validated instruments in general or primary-care settings to identify individuals with a high probability of a depressive or anxiety disorder, who then require confirmatory clinical assessment.

Scope

The topic covers the rationale for screening, the principal self-report instruments (notably the PHQ-9 for depression and the GAD-7 for generalised anxiety), the interpretation of screening as case-finding rather than diagnosis, and the condition that screening be coupled with systems for accurate diagnosis and follow-up. It is a reference entry on the screening method, not a protocol for diagnosing or treating any individual.

Core questions

• Which validated instruments perform adequately for detecting depression and anxiety in primary care, and at what thresholds?
• Whom should be screened, and how often?
• What follow-up systems must accompany screening for it to improve outcomes?

Key concepts

• Case-finding versus diagnosis
• PHQ-9 (Patient Health Questionnaire)
• GAD-7 (Generalized Anxiety Disorder scale)
• Sensitivity, specificity, and cut-point selection
• Two-stage screening (ultra-brief then full instrument)
• Screening linked to diagnosis and follow-up

Mechanisms

Screening instruments translate symptom reports into scores that, above a chosen threshold, flag a high probability of disorder. The PHQ-9 maps the nine DSM depression criteria onto a 0-27 severity score, and the GAD-7 provides an analogous brief measure for generalised anxiety; ultra-brief versions (PHQ-2, GAD-2) can serve as a first stage. A positive screen is not a diagnosis: it identifies people who warrant structured clinical assessment. The health benefit of screening arises only when positive results are linked to accurate diagnosis, effective treatment, and follow-up.

Clinical relevance

Screening underlies national recommendations to detect depression and anxiety in adults in settings where follow-up can be ensured, and instruments such as the PHQ-9 and GAD-7 are also used to gauge symptom severity over time. This entry describes how screening is conducted and interpreted; it is educational and does not direct the diagnosis or management of any individual.

Epidemiology

Depressive and anxiety disorders are common in primary care yet frequently undetected without systematic enquiry. Pooled diagnostic-accuracy data indicate that the PHQ-9 at its standard cut-point provides moderate sensitivity and high specificity for major depression, and the GAD-7 performs comparably for generalised anxiety. The US Preventive Services Task Force recommends screening adults, including pregnant and postpartum persons, for both depression and anxiety disorders.

History

Brief office screening for common mental disorders grew from the PRIME-MD program of the 1990s, from which the self-administered Patient Health Questionnaire and its PHQ-9 depression module were derived in 2001; the GAD-7 followed in 2006 as a brief generalised-anxiety measure. Individual-participant-data meta-analysis later refined understanding of PHQ-9 accuracy, and successive US Preventive Services Task Force statements extended formal screening recommendations to depression and, in 2023, to anxiety disorders in adults.

Debates

Does universal screening improve outcomes beyond good clinical care?

Screening is recommended where follow-up systems exist, but critics note that benefit depends on linkage to effective treatment and caution against detection without adequate care pathways; the marginal value of universal screening over case-based enquiry remains discussed.

Key figures

• Kurt Kroenke
• Robert Spitzer
• Janet Williams

Seminal works

• kroenke-2001
• spitzer-2006
• uspstf-depression-2023

Frequently asked questions

Does a positive depression or anxiety screen mean a person has the disorder?

No. A positive screen indicates a high probability and signals the need for a confirmatory clinical assessment; screening instruments identify candidates for evaluation rather than establishing a diagnosis.

What are the most commonly used screening tools?

The PHQ-9 is widely used for depression and the GAD-7 for generalised anxiety; their ultra-brief two-item versions, the PHQ-2 and GAD-2, are sometimes used as a first stage.